Dr Kluge told the UN Geneva Palais Briefing: ‘Mpox is not the “new COVID”.
‘Regardless of whether it’s mpox clade I, behind the ongoing outbreak in east-central Africa — or mpox clade II, behind the 2022 outbreak that initially impacted Europe — and has continued to circulate in Europe since.
‘We know quite a lot about clade II already. We still have to learn more about clade I.
‘Based on what we do know, mpox primarily transmits through skin-to-skin contact with mpox lesions, including during sex.’
He added: ‘Today, we’re seeing about 100 new mpox clade II cases in the European Region every month.
‘However, the current state of alert due to clade I gives Europe the opportunity to refocus on clade II.
Read More
Everything you need to know about Mpox – including warning signs
‘Two years ago, we controlled mpox in Europe thanks to the direct engagement with the most affected communities of men who have sex with men.
‘We put in place robust surveillance, we thoroughly investigated new cases contacts and we provided sound public health advice.
‘Behaviour change, non-discriminatory public health action, and mpox vaccination contributed to controlling the outbreak.
‘Learning from our success, we urged governments and health authorities to sustain those measures — to help eliminate mpox from Europe.
‘But through a lack of commitment and a lack of resources we failed to go the last mile.
‘In sum, even as we strengthen vigilance against mpox clade I, we can — and should — strive to eliminate clade II in Europe for once and for all.’
Latest WHO data shows more than 99,000 mpox cases have been logged globally since January 2022.
Clade II sparked alarm among health officials in 2022, however, new infections gradually tapered off amid boosted awareness of the disease and a hurried vaccination program.
At the time the UK reported almost 4,000 cases of this less severe form of mpox, with NHS England inoculating over 68,000 people against the disease with the smallpox vaccine, which works due to the two viruses being closely related.
+8
View gallery
The smallpox vaccine has been known to help prevent mpox due to the two viruses being closely related. But experts said there wasn’t yet enough evidence to suggest a vaccine would be effective against the new clade 1b strain
+8
View gallery
Clade II sparked alarm among health officials in 2022, however, new infections gradually tapered off amid boosted awareness of the disease and a hurried vaccination program. During the outbreak thousands of cases were recorded in the UK, mostly in London
The UK Health Security Agency (UKHSA) has already cautioned it is ‘already planning’ for UK cases.
Dr Meera Chand, deputy director at the UKHSA, said the current threat to the UK by the new mpox strain is ‘currently considered low’.
But she added: ‘However, planning is underway to prepare for any cases that we might see in the UK.’
Rapid testing is being made available and GPs and hospitals have been told to isolate those with potential symptoms.
Pat McFadden, the chancellor of the Duchy of Lancaster, also met with ministers from the Department for Health, Foreign Office and the UK’s chief medical officer Professor Sir Chris Whitty on Monday.
They met to ‘ensure sufficient plans are in place to deal with any potential cases’ Downing Street said.
Mpox, also known as monkeypox, causes characteristic lumpy lesions, as well as a fever, aches and pains and fatigue.
However, in a small number of cases, it can enter the blood and lungs, as well as other parts of the body, when it becomes life-threatening.